Related Experiment Video
Updated: May 12, 2026

Mouse Model of Metabolic Dysfunction-Associated Steatotic Liver Disease with Fibrosis
Published on: July 18, 2025
Hepatopulmonary syndrome as presentation of pediatric metabolic dysfunction-associated steatohepatitis
Shruti Sakhuja1, Stacey S Beer1, Kalyani R Patel2
1Department of Pediatrics, Division of Gastroenterology, Hepatology, and Nutrition Baylor College of Medicine and Texas Children's Hospital Houston Texas USA.
Abstract:
Childhood obesity is rising and leading to serious co-morbidities, among which is metabolic dysfunction-associated steatotic liver disease (MASLD) predisposing individuals to cirrhosis. We describe a young 11-year-old Hispanic male who presented with hepatopulmonary syndrome secondary to cirrhotic portal hypertension from metabolic dysfunction-associated steatohepatitis (MASH), necessitating liver transplantation. Despite lifestyle modifications post-transplantation, the patient experienced persistent weight gain and recurrence of steatosis, emphasizing challenges of managing pediatric MASLD. The burden of childhood obesity is increasing and impacting children significantly earlier than previously believed. Our case is one of the few to report the severe complications of MASH in a young, pre-teen child necessitating early liver transplantation. Furthermore, the case highlights the evolving landscape of pediatric liver transplant, with MASH increasingly recognized as an indication for pediatric liver transplantation. The management of this disease is challenging and requires a multidisciplinary approach.
Related Concept Videos
Pharmacokinetics in Pediatric Patients: Drug Metabolism
Inborn Errors of Metabolism
Hepatic Encephalopathy
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Cirrhosis II: Pathophysiology
Portal Hypertension
